This study showed that a SBP of 120 to 129 mmHg was associated with the lowest risk of adverse outcomes in HFpEF. SBP lowering does not explain the treatment effects of sacubitril/valsartan.

The FDA approved dapagliflozin for treatment of heart failure patients with reduced ejection fraction to reduce CV death and hospitalization for HF.

ACC 2020 The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.

ACC 2020 The VICTORIA trial demonstrated that therapy with the sGC stimulator vericiguat reduced the primary endpoint in HFrEF patients with worsening HF condition compared to placebo.

This prospective registry study of a real-world cohort of elderly HFrEF patients showed that sacubitril/valsartan was safe and effective, even in those >80 years.

AHA 2019 A prespecified analysis of PARADIGM-HF and PARAGON-HF data allowed assessment of the effect of sacubitril/valsartan across the spectrum of ejection fractions.

AHA 2019 As a discussant of the pooled PARAGON-HF and PARADIGM-HF data, dr. Stevenson critically considers the results to get physiological clues on who should be treated and who may not benefit of ARNI therapy.

AHA 2019 Prof. Kosiborod describes a substudy of the DAPA-HF trial which examined whether dapagliflozin resulted in improvement of symptoms, physical limitations and QoL compared to placebo in HFrEF.

EPCCS 2019 Monika Hollander asks Peter van der Meer how comorbidities like renal dysfunction and cancer treatment affects management of patients with HF: what is known about treatment in patients with these comorbidities?

ESC 2019 DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.

ESC 2019 The BB-meta-HF group combined double-blind, individual patient-level data and confirmed that beta-blockers are efficient in HFrEF patients in sinus rhythm with moderately-severe renal dysfunction.

EPCCS 2019 Professor Peter van der Meer & Monika Hollander consider new recommendations in the latest ESC Guidelines on diagnosis and treatment of patients with HF, and the role GPs may play in this process.